QIAGEN N.V. (QGEN) Stock News
NYSE:QGEN - New York Stock Exchange, Inc. - NL0015002CX3 - Common Stock - Currency: USD
QGEN Latest News, Press Relases and Analysis
QIAGEN N.V. (NYSE:QGEN) – A Quality Stock Worth Considering
QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid cash flow conversion, making it a candidate for long-term investors.
QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
Incyte Corporation (NASDAQ:INCY) is one of the 10 biotech stocks screaming a buy. On June 17, Incyte was a big mover in the market, announcing the signing of a strategic partnership with Netherlands QIAGEN N.V. QGEN. The two are coming together to enhance the development of a novel diagnostic panel to support investigational treatments for […]
Here's Why Qiagen (QGEN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism
Stifel also upgraded the stock to ‘Buy’ with a $107 price target.
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing […]
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: INCY
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.
KeyBank adopts Personetics platform to enhance client engagement
The collaboration will see KeyBank implement Personetics’ “Engage”, a client-facing tool designed to provide personalised financial insights.
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
/PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced...
Qiagen and ID Solutions Partner to Enhance Digital PCR Assays for Oncology Research
On Friday, Qiagen (NYSE:QGEN) announced a new commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for oncology research applications. The partnership aims to use Qiagen’s global reach and automation expertise with ID Solutions’ assay development and manufacturing capabilities to strengthen Qiagen’s […]
QGEN Stock Might Gain Following New Partnership With ID Solutions
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Qiagen (QGEN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
QIAGEN Stock Gains Following the Acquisition of Genoox
QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio.
QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up
QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 10% and 4.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: YMAB
QIAGEN announces plans for transition in leadership of Supervisory Board
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Qiagen (QGEN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 28.57% and 21.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ADPT
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: SGMO
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ARQT
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance
Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%.